Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -161.63% is 4126% below its 5-year average of 4.01%, near the low end of its 5-year range (-161.63%–20.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 77.45% below its 12-month average of -91.08%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -161.63%.
RETURN ON EQUITY (ROE)
-161.63%
RETURN ON EQUITY (ROE) AVG TTM
-91.08%
RETURN ON EQUITY (ROE) AVG 3Y
1.36%
RETURN ON EQUITY (ROE) AVG 5Y
4.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.45%
CURRENT VS 3Y AVG
-11961.22%
CURRENT VS 5Y AVG
-4126.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 585 covered companies
CURRENT VS SECTOR MEDIAN
-308.66%
vs the sector median at left
DocGo Inc.
Market Cap
$36.31M
Return on Equity (ROE)
-161.63%
TTM Avg
-91.08%
3Y Avg
1.36%
5Y Avg
4.01%
Market Cap
$36.99M
Return on Equity (ROE)
-476.77%
TTM Avg
-979.99%
3Y Avg
-646.46%
5Y Avg
-421.61%
Market Cap
$36.99M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$35.52M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
Market Cap
$35.15M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$34.54M
Return on Equity (ROE)
-117.97%
TTM Avg
-59.96%
3Y Avg
-42.92%
5Y Avg
-31.82%
Market Cap
$38.35M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$34.18M
Return on Equity (ROE)
-44.50%
TTM Avg
-16.33%
3Y Avg
-36.34%
5Y Avg
-33.52%
Market Cap
$34.10M
Return on Equity (ROE)
-238.24%
TTM Avg
203.84%
3Y Avg
55.01%
5Y Avg
16.87%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DocGo Inc. (DCGO) | $36.31M | -161.63% | -91.08% | 1.36% | 4.01% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.99M | -476.77% | -979.99% | -646.46% | -421.61% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | -160.05% | -184.57% | -168.71% | -141.15% |
| Elutia Inc (ELUT)vs › | $35.52M | 329.02% | 154.76% | 265.18% | 128.71% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | -154.06% | -1.75% | 68.54% | 60.27% |
| Accuray Incorporated (ARAY)vs › | $34.54M | -117.97% | -59.96% | -42.92% | -31.82% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -28.65% | -189.41% | -194.44% | -158.64% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.18M | -44.50% | -16.33% | -36.34% | -33.52% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $34.10M | -238.24% | 203.84% | 55.01% | 16.87% |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.33M | -140.36% | -216.21% | -112.57% | -76.80% |
ROE
-161.6%
ROA
-103.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -161.63% |
| 2026-03-31 | -141.91% |
| 2025-12-31 | -126.66% |
| 2025-09-30 | -19.07% |
| 2025-06-30 | -6.16% |
| 2025-03-31 | -0.21% |
| 2024-12-31 | 6.23% |
| 2024-09-30 | 9.48% |
| 2024-06-30 | 9.55% |
| 2024-03-31 | 6.92% |
| 2023-12-31 | 2.28% |
| 2023-09-30 | 2.56% |
| 2023-06-30 | 2.05% |
| 2023-03-31 | 7.35% |
| 2022-12-31 | 12.66% |
| 2022-09-30 | 18.95% |
| 2022-06-30 | 20.41% |
| 2022-03-31 | 15.54% |
| 2021-12-31 | 10.81% |
| 2021-09-30 | -7.65% |
| 2021-06-30 | -19.44% |
| 2021-03-31 | -19.76% |
| 2020-12-31 | -27.23% |
